Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/07/21 | $54,000,000 | Series C |
Meritech Capital Partners True Ventures | undisclosed |
